Home › Companies › EIKN

Eikon Therapeutics

Market cap $279M 54.2M shares (10-Q, Nov 2, 2026) × $5.15 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. EIK1004 readout2H 2026EIK1004 readout, 2H 2026, notable
  2. TeLuRide-008 interim2H 2027TeLuRide-008 interim, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (13 active programs)

Technology platforms

SMT

Single molecule tracking platform integrating custom-engineered super-resolution microscopy, bespoke automation, advanced data science ML/AI tools, and petabyte-scale data processing. Used to identify and validate novel targets, elucidate mechanisms of action, and accelerate drug candidate identification. Focus areas: oncology and neurologic disease.

single molecule tracking

Proprietary single molecule tracking system used to enable drug discovery and development of internally derived novel oncology therapies; EIK1005 emerged through application of this advanced imaging discovery platform.

Capital (as filed)

Cash
$98.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$363M Sep 30, 2026
Operating cash flow
−$69.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$462M cash, runway Q1 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (6)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (6 calls)

Every verdict Biotech Distilled has published on Eikon Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Eikon Therapeutics (EIKN) — Scientific Deep Dive for EIK1001, EIK1003, and Pipeline Products Un-patentable lead molecule, single-arm confidence intervals that swallow the SOC benchmark, and an unresolved licensor payment dispute keep the stock on the sidelines until the randomized TeLuRide-006 melanoma interim reads out.
  2. Watch UPDATE: Eikon Therapeutics (EIKN) - The DMC Picked the Low Dose DMC dose selection removes catastrophic-interim risk but discloses zero efficacy data; the named trigger — randomized melanoma efficacy interim — has not fired.
  3. Watch UPDATE: Eikon Therapeutics (EIKN) - The Dispute Quietly Died, the Burn Did Not Seven and Eight licensor dispute resolved (one bear pillar gone), but burn accelerated 77% YoY and no efficacy data moved; named trigger still not fired.
  4. Watch UPDATE: Eikon Therapeutics (EIKN) - The Undercard Fight ESMO day-one data confirms PARP1 blood-sparing for EIK1004 but shows no EIK1001 efficacy; named trigger (randomized melanoma interim) still undated and unfired.
  5. Watch UPDATE: Eikon Therapeutics (EIKN) - The Durability Test Splits Down the Middle Non-squamous DOR resolved below KEYNOTE-189 benchmark and first randomized NSCLC read slipped to 2H 2027; NSCLC leg weakened and a dilutive raise before randomized proof now more likely, but named trigger unchanged.
  6. Watch UPDATE: Eikon Therapeutics (EIKN) - The Trigger Slips, the Runway Stretches Melanoma interim slipped to 1H 2027 and reframed as a futility test, but extended runway now reaches past the readout, reducing forced-raise risk; trigger reset but still unfired.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (6 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)